Upon the comparison of DLI products applied to patients with and without future development of GVHD, we observed no differences, neither in the CD4+CD25+CD127low Treg nor in the CD4+ Tcon repertoire (Supplementary Figure S4A–C). Here, CD4 is linked to graft versus host disease.